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2ABSTRACT 
 
In vertebrates, homologous recombinational repair (HRR) requires RAD51 and five RAD51 paralogs 
(XRCC2, XRCC3, RAD51B, RAD51C, and RAD51D) that all contain conserved Walker A and B 
ATPase motifs. In human RAD51D we examined the requirement for these motifs in interactions with 
XRCC2 and RAD51C, and for survival of cells in response to DNA interstrand crosslinks. Ectopic 
expression of wild type human RAD51D or mutants having a non-functional A or B motif was used to 
test for complementation of a rad51d knockout hamster CHO cell line. Although A-motif mutants 
complement very efficiently, B-motif mutants do not. Consistent with these results, experiments using the 
yeast two- and three-hybrid systems show that the interactions between RAD51D and its XRCC2 and 
RAD51C partners also require a functional RAD51D B motif, but not motif A. Similarly, hamster Xrcc2 
is unable to bind to the non-complementing human RAD51D B-motif mutants in co-immunoprecipitation 
assays. We conclude that a functional Walker B motif, but not A motif, is necessary for RAD51D’s 
interactions with other paralogs and for efficient HRR. We present a model in which ATPase sites are 
formed in a bipartite manner between RAD51D and other RAD51 paralogs. 
3INTRODUCTION 
 
DNA double-strand breaks (DSBs) represent a severe form of DNA damage that can lead to mutations 
and cell death if repaired incorrectly. Cells have evolved multiple mechanisms to repair DSBs, including 
the high fidelity process of homologous recombinational repair (HRR) (1,2), which contributes 
significantly to the repair of DSBs in cycling cells (3), such as those generated at the replication fork 
during interstrand crosslink (ICL) removal. In vertebrates, HRR is highly conserved and mediated by the 
bacterial RecA ortholog, the Rad51 recombinase, and five Rad51 paralogs (XRCC2, XRCC3, Rad51B, 
Rad51C and Rad51D). Though the biochemical functions of these paralogs in HRR are not well 
understood, they have been proposed to function in early steps (4-7) and in late steps (7-11) of 
recombination. The Rad51 paralogs are necessary for cellular resistance to DSBs (12,13), have no 
functional redundancy (14) and share limited sequence homology with Rad51 and with each other (~20% 
identity; reviewed in (15)). The regions of highest sequence homology are the putative ATP-binding 
domains: the conserved Walker A and Walker B motifs (12,13,15,16).  
 In human cells, several RAD51 paralog complexes have been identified, among them the RAD51B-
RAD51C-RAD51D-XRCC2 heterotetramer, and three heterodimers: RAD51B-RAD51C, RAD51D-
XRCC2 and RAD51C-XRCC3 (4,17-24). The RAD51B-RAD51C and RAD51D-XRCC2 complexes 
were shown to bind to single- and double-stranded DNA and to hydrolyze ATP, an activity enhanced by 
DNA binding (4,19,25,26). The heterotetramer also exhibits ATPase activity and preferentially bound to 
Y-shaped DNA and synthetic Holliday junctions (27).  
 The Walker ATPase domain (28) consists of two separate motifs, A and B, crucial components of the 
nucleotide-binding site. The lysine residue in the GKT/S box of the Walker A motif is essential for ATP-
binding and contacts the -phosphate of the nucleotide (29). The highly conserved aspartate/glutamate of 
the Walker B motif forms hydrogen bonds with the threonine/serine of the GKT/S box and with a bound 
water molecule (30) and facilitates nucleotide hydrolysis. 
 In human RAD51, non-conservative (no ATP binding) K133A substitution in the Walker A motif did 
not rescue the Rad51-deficient lethality of chicken DT40 cells while the conservative (ATP binding, but 
no hydrolysis) K133R substitution only gave a partially defective phenotype (31). In in vitro assays, 
human RAD51-K133R showed an increased stability of presynaptic filament formation and enhanced 
homologous pairing activity compared to the wild type protein (32), but in a dominant-negative approach, 
expression of human RAD51-K133R in a mouse embryonic stem cell line specifically inhibited 
homology-directed DSB repair (33). In the Walker B motif of human RAD51, mutation in the highly 
conserved aspartate (D222A), but not V221A or S223A, was shown to eliminate protein function in the 
DT40 system (31). For the human RAD51 paralogs, mutations within the Walker A motif of RAD51C 
and XRCC3 were shown to greatly reduce cellular resistance to interstrand crosslinks (ICLs) (34,35), but 
mutation in the Walker A motif in XRCC2 had little effect on complementing ability (36). Substitution of 
the conserved aspartate residue in the Walker B motif of human XRCC3 (D213N) resulted in increased 
spontaneous apoptosis and complete loss of gene-complementing activity for cell survival to ICL damage 
in the CHO xrcc3 mutant (37,38). Evidence suggests that nucleotide binding and hydrolysis play 
important roles in the formation of RAD51 paralog complexes. For example, in XRCC3, the inability to 
hydrolyze bound ATP (i.e. a Walker A GRT substitution) blocks the interaction with RAD51C (35). A 
study of the paralog interactions of mouse Rad51D Walker A mutants has also been reported (39), and 
these results are discussed later.  
 In this study, Walker-motif mutants of RAD51D were tested for their ability to complement the 
MMC sensitivity of CHO RAD51D knockout cells ((hereafter written as rad51d cells); (2)). Surprisingly, 
RAD51D mutants of the GKT box of the Walker A motif rescued the MMC sensitivity of rad51d cells, 
whereas B-motif mutants did not complement. In addition, whereas A-motif mutations had little effect on 
the interaction of RAD51D with binding partners XRCC2 and RAD51C, mutations in the B-motif 
disrupted these interactions. These results constitute the novel finding of a differential requirement for the 
Walker A and B motifs of a human ATPase. 
 
4EXPERIMENTAL PROCEDURES 
 
Cell culture 
 
Parental CHO cells (strain AA8) and 51D1Lox and 51D1 (rad51d) derivatives (2) were grown in 
monolayer or suspension cultures in MEM-alpha medium supplemented with 10% fetal bovine serum, 
100 Jg/ml streptomycin and 100 U/ml penicillin. For the experiments involving chronic MMC exposures 
and the generation of denatured and crude protein lysates from rad51d derivatives, cells were grown 
under selection in 700 µg/ml hygromycin B.  
 
Human RAD51D expression plasmids 
 
The RAD51D cDNA was PCR amplified from plasmid pDS200 (40) and subcloned into pcDNA3.1/hygro 
(Invitrogen) from HindIII to NheI. The entire RAD51D open reading frame (ORF) was verified by direct 
sequencing. Mutations were introduced using the QuickChange Site-directed mutagenesis II kit 
(Stratagene), and missense mutations were confirmed by direct sequencing of the entire ORF. Mutagenic 
primers were designed to create the following changes to the amino acid sequence of RAD51D: K113R, 
5’-GGCCCAGGTAGCGGCCGCACTCAGGTATGTCTCTGTATGGC-3’; K113A, 5’-
GGCCCAGGTAGCGGCGCTACTCAGGTATGTCTCTGTATGGC-3’; V203E, 5’-
GGAACTGTGAAGGTGGAGGTTGTGGACTCGGTCACTGCGG-3’; and D206A, 5’-
GGAACTGTGAAGGTGGTGGTTGTGGCTTCGGTCACTGCGG-3’ (only forward primers are shown; 
reverse primers had the complementary sequence). 
 
Yeast two- and three-hybrid system 
 
The yeast strain Y190-ura- (40) was used for all yeast two- and three-hybrid experiments. For yeast two-
hybrid analyses, Y190-ura- was co-transformed with both a DNA-binding domain (pGBT9; (41)) and a 
transcription-activating domain fusion plasmid (pGAD424; (41)) and transformants were recovered on 
selective media (i.e. synthetic complete media lacking leucine and tryptophan: SC -Leu, -Trp). For yeast 
three-hybrid analyses, RAD51B was expressed from pVT100U, a yeast expression vector containing the 
URA3 selectable marker (42) as described in (40). To test three-hybrid interactions, strains containing two 
plasmids, grown in SC -Leu, -Ura, were transformed with the third plasmid, derived from pGBT9, and 
selected on plates lacking leucine, tryptophan and uracil. Four independent colonies for all 
transformations were assayed qualitatively for -galactosidase activity using X-gal filter assay (43). To 
quantify the strength of protein-protein interactions, liquid -galactosidase assays were performed using 
o-nitrophenyl--galactopyranoside (Sigma) as a substrate as described (43). All quantitative -
galactosidase activity assays were performed on three to five independent colonies, each monitored in 
triplicate. Standard error of the mean (SEM) was determined among independent colonies. Yeast two-
hybrid plasmids for RAD51D, XRCC2 and RAD51C are described in (40). Mutations were introduced into 
the RAD51D using site-directed mutagenesis and mutagenic primers as described above. Mutations were 
introduced into the XRCC2 ORF using the QuickChange Site-directed mutagenesis II kit (Stratagene). 
Missense mutations were confirmed by direct sequencing of the entire ORF. Mutagenic primers for 
XRCC2 were designed as follows: K54R, 5’-GGCCCAGAAGGAACAGGACGCACAGAAATGC-3’; 
K54A, 5’-GGCCCAGAAGGAACAGGAGCTACAGAAATGC-3’; L148S, 5’-
5GCCTTTTGATTTTGGCCAGCCTGTCAGCTTTTTACTGG-3’; D148A, 5’-
GCCTTTTGATTTCAGATAGCCTGTCAGCTTTTTACTGG-3’; (only forward primers are shown; 
reverse primers had the complementary sequence). 
 
Whole cell protein extracts from transformed yeast strain Y190U-ura-
To monitor the expression levels of Gal4-RAD51D in Y190U-ura- transformants, whole cell protein 
extracts were generated according to published procedures (44). Western blot analysis was carried out as 
described elsewhere (22), and filters were probed with 1:2000 diluted primary anti-RAD51D (Novus 
Biologicals). The signal for actin (dilution 1:300; Santa Cruz Biotech.) was used as a loading control. 
Detection was carried out using horseradish peroxidase-conjugated goat anti-rabbit secondary antibody 
(Jackson ImmunoResearch; 0.4 mg/ml). Filters were incubated with Supersignal WestPico substrate kit 
(Pierce Chemical) followed by exposure to Hyperfilm ECL (Amersham Biosciences). 
 
Expression and purification of recombinant RAD51D and XRCC2 by affinity chromatography 
 
For recombinant expression of GST-XRCC2 and His6-RAD51D, respective cDNAs were inserted into the 
baculovirus transfer vector pFASTBACTM DUAL (Invitrogen). The GST ORF flanked by a PreScission 
Protease cleavage site was inserted upstream and in frame with the XRCC2 ORF. For PCR amplification 
of the RAD51D cDNA an N-terminal His6-tag was built in the forward primer. Proteins were expressed in 
Sf9 insect cells and purified to 80% homogeneity. One L of insect cell culture was harvested at 72 h post-
infection, and cells were pelleted at 1600 × g and resuspended in 20 ml of cell lysis buffer (20 mM Hepes 
pH 8.0, 100 mM NaCl, 10% glycerol, 0.5 mM phenylmethylsulfonylfluoride (PMSF), 5 µg/ml aprotinin 
and 5 µg/ml leupeptin). The cell suspension was incubated on ice for 20 min, sonicated, and clarified by 
ultracentrifugation at 110,000 × g for 20 min. The supernatant was applied to a 5-ml Glutathione 
Sepharose 4 FF column (Amersham Biosciences) equilibrated with 10 column volumes buffer A (1 ×
phosphate buffered saline, 10% glycerol). Bound GST-XRCC2:His6-RAD51D complex was washed with 
10 column volumes buffer A and eluted with buffer B (10 mM glutathione, 50 mM Tris-HCl pH 8.0, 10% 
glycerol). Peak fractions were pooled and dialyzed into PreScission Protease cleavage buffer (50 mM 
Tris-HCl pH 8.0, 150 mM NaCl, 1 mM EDTA, 10% glycerol, 1 mM DTT, 0.5 mM PMSF, 5 µg/ml 
aprotinin and 5 µg/ml leupeptin) for subsequent cleavage by PreScission Protease according to the 
manufacturer’s description (Amersham Biosciences). Following cleavage, the protein was diluted 1:1 
with 100% glycerol and stored at -80°C.  
 
Transfection of rad51d cells  
 
Transfectants of rad51d cells (2) that stably express wild type or mutant human RAD51D protein were 
created by electroporation (625 V/cm, 950 µF) using Gene Pulser II (Bio-Rad). 1 × 106 cells were 
electroporated in 400 µl cytomix buffer using 10 µg of linearized plasmid (45). Twenty-four hours post-
transfection, cells were plated into 10-cm dishes at ~ 104 cells/dish in 20 ml of medium containing 
hygromycin B (700 µg/ml) and incubated for 12 days for colony formation. Ten colonies were isolated 
and expanded for each transfected plasmid and analyzed for expression of the transgene by Western blot 
analysis (22). Filters were probed with 1:2000 diluted primary anti-RAD51D (Novus Biologicals). The 
signal for the transcription factor QM (dilution 1:10,000; Santa Cruz Biotech.) was used as a loading 
control. Detection was carried out using horseradish peroxidase-conjugated goat anti-rabbit secondary 
antibody (Jackson ImmunoResearch; 0.4 mg/ml). Filters were incubated with Supersignal WestPico 
substrate kit (Pierce Chemical) followed by exposure to Hyperfilm ECL (Amersham Biosciences). 
 
6Genetic complementation analysis  
 
MMC sensitivity was determined by colony formation assay in 10-cm dishes. Exposure to MMC (Sigma) 
was conducted in 10-ml suspension cultures. For each dose, 1 × 106 cells were exposed to MMC for 60 
min at 37°C, centrifuged, and resuspended in fresh medium for plating. For each dose, 300 or more cells 
were plated in triplicate. After 12 days of growth, dishes were rinsed with saline, fixed with 95% ethanol 
and stained with Gram Crystal Violet. Colonies with > 50 cells were scored. 
 To test for complementation directly in transfected cell populations, transfections were carried out as 
described above. Twenty-four hours post-transfection, cells were trypsinized and re-seeded at 4 × 104
cells/well in 6-well plates in regular growth medium containing hygromycin B without MMC, or with 
MMC at various concentrations. Colonies were fixed and stained after 12 days of growth. The surviving 
fraction of colonies was calculated as the ratio of the number of colonies in selection in MMC and 
hygromycin B to the number of colonies in the presence of hygromycin B only. For comparison purposes, 
untransfected AA8 were plated at 200 cells/well in regular growth medium lacking hygromycin B, both 
with and without MMC. In addition, rad51d cells were transfected with the empty vector control 
(pcDNA3.1/hygro) and plated at 4 × 104 cells/well in regular growth medium containing hygromycin B 
without or with MMC. The transfection efficiencies for all plasmids used were determined in a separate 
experiment. Plasmids were electroporated as described above and cells were plated 24 hr post transfection 
in regular growth medium containing hygromycin B. The stable transfection efficiencies were found to be 
similar for all plasmids used and were 0.27 ± 0.03%. 
 
Immunoprecipitation 
 
Immunoprecipitation was performed as previously described (22) using native cellular protein extracts 
from untransfected rad51d and AA8 cells and rad51d cells stably expressing either wild type or mutant 
RAD51D. Immunoprecipitation was carried out using MagnaBind goat anti-rabbit IgG magnetic beads 
(Pierce) and anti-RAD51D antibody (Novus Biologicals) or control antibody (rabbit IgG, Santa Cruz 
Biotech.). The polyclonal rabbit anti-human XRCC2 antibody for direct immunoprecipitation of hamster 
Xrcc2 was kindly provided by Dr. P. Sung. Western blots were probed with 1:2000 diluted primary anti-
RAD51D and 1:1000 diluted primary anti-XRCC2 antibody (Santa Cruz Biotech.). Detection was carried 
out using horseradish peroxidase-conjugated goat anti-rabbit secondary antibody (see above) or bovine 
anti-goat secondary antibody (1:10,000; Santa Cruz Biotech.). Filters were incubated as described above 
for analysis of RAD51D-expressing rad51d cells. To visualize co-immunoprecipitated hamster Xrcc2, 
filters were incubated with ECL-Advance (Amersham Biosciences). 
 
RESULTS 
 
Complementation of rad51d cells by ectopic expression of wild type human RAD51D 
 
Following transfection of rad51d cells (clone 51D1; (2)) with the wild type RAD51D expression 
construct, colonies were selected for hygromycin resistance. To test whether these clones stably expressed 
the human cDNA, we picked 10 independent colonies and expanded them to mass cultures for Western 
blot analysis. As shown in Fig.1A, seven of these clones stably expressed the transgene. Since the 
expression levels for RAD51D protein varied, one clone expressing a lower level of the protein (WT1; 
7WT for wild type) and one expressing a higher level (WT2) were selected to test whether ectopic 
expression of human RAD51D rescued the very high (~80-fold) MMC sensitivity of rad51d cells (2). 
Using the colony formation assay for cell survival, we found that both clones WT2 and WT1 were 
efficiently complemented; their MMC resistance was similar to that of the wild type AA8 cells (Fig. 2A
and 2B, respectively). We also observed that the parent of 51D1, 51D1Lox, which contains functional 
Rad51D alleles prior to Cre-recombinase treatment (2), was slightly more sensitive to MMC (~2-fold; 
determined form D37 values) than AA8 cells or rad51d cells expressing wild type human RAD51D (Fig. 
2A and 2B). We explain this observation in part by the fact that the endogenous hamster Rad51D protein 
level in AA8 cells (and possibly the human protein in clones WT1 and WT2) is higher than in 51D1Lox 
cells (2). However, due to interspecies variation in antibody recognition it is not possible for us to 
compare the protein levels in 51D1Lox cells (i.e. hamster Rad51D) to that in the transfectants (i.e. human 
RAD51D).  
 
Complementation of rad51d cells by ectopic expression of RAD51D Walker A-motif ATPase 
mutants  
 
We tested whether a conservative amino acid substitution (K113R; binds but does not hydrolyze ATP), or 
a non-conservative substitution (K113A; unable to bind ATP), in the GKT box of the Walker motif A 
influenced the ability of RAD51D to complement the rad51d mutant. We transfected rad51d cells with 
each mutant construct (GRT and GAT; see Fig. 1E) and isolated 10 independent clones for each mutant. 
As shown in Fig. 1B and 1C by Western blot analysis, the protein expression levels of independent clones 
stably expressing either mutant of RAD51D varied. As with the cells expressing the wild type RAD51D 
construct, for each mutant we choose a low-expressing clone (GAT2 and GRT3 (GRT2 was added in 
follow-up experiments); see Fig. 1, panels C and B, respectively), and a high expressing clone (GRT6 and 
GAT4; see Fig. 1, panels B and C, respectively). We found that stable expression of either mutant protein 
largely complemented MMC sensitivity of rad51d cells (Fig. 2A and 2B). The degree of MMC resistance 
of the high-expressing lines (GRT6 and GAT4) was similar to that of AA8 cells and rad51d cells 
expressing wild type RAD51D (WT2) (Fig. 2A). For the low-expressing lines (GRT2, GRT3 and GAT2), 
complementation was less complete (~2- to 3-fold lower, as determined from the D37 values (Fig. 2B)). 
However, these lower expressing lines were clearly no more sensitive to MMC than parental 51D1Lox 
cells that express reduced levels of hamster Rad51D (Fig. 2B; (2)).  
 
No complementation of rad51d cells by ectopic expression of RAD51D Walker B-motif ATPase 
mutants 
 
Since we observed almost no abnormality in cellular phenotype for the Walker A-motif mutations, we 
hypothesized that the Walker B motif may predominately determine the function of RAD51D. To test this 
possibility, we mutated the highly conserved aspartate (D206) to alanine (D206A; see Fig. 1E). For 
comparison purposes, we also made the previously uncharacterized V203E substitution within motif B of 
RAD51D. This valine was chosen for mutagenesis as it is conserved among the human RAD51 paralogs 
RAD51B, RAD51C, RAD51D and XRCC3, and in mouse and hamster Rad51D. Both expression 
constructs (V203E and D206A) were separately transfected into rad51d cells, and cells were selected in 
the continuous presence of either hygromycin alone or hygromycin plus increasing concentrations of 
MMC. The extent of complementation for expression of all RAD51D constructs was assessed by 
comparing the number of colonies arising in hygromycin and MMC to the number of colonies arising in 
hygromycin alone. As shown in Fig. 2C, ectopic expression of either RAD51D-V203E or RAD51D-
8D206A does not result in complementation of MMC sensitivity of rad51d cells measured by colony 
formation. Conversely, in this same method of analysis, expression of wild type RAD51D, or the Walker 
A box mutants RAD51D-K113R and RAD51D-K113A resulted in high MMC resistance (Fig. 2C) albeit 
expression of either K113R or K113A did not fully protect against killing. Whether these latter modest 
reductions are biochemically significant is unclear since the expression levels of the A-motif mutant 
proteins could be slightly lower than that of wild type. As with the A-motif mutants, both B-motif 
mutants are expressed stably in rad51d cells (Fig. 1D).  
 
Inability of RAD51D Walker B mutants to interact with XRCC2 in the yeast two-hybrid system 
 
As RAD51D B-motif mutants are unable to repair MMC-induced DNA damage, we investigated whether 
disruptions occur in the interactions between RAD51D and its known paralog partners. To do so, we 
employed the yeast two- and three-hybrid systems and tested whether mutant RAD51D would be able to 
interact with either XRCC2 or RAD51C. Each of the described forms of RAD51D (wild type, K113R, 
K113A, V203E and D206A) was generated by site-directed mutagenesis using previously described 
vectors carrying wild type RAD51D (40). First, each RAD51D protein was tested for binding to wild type 
XRCC2 in both orientations (Fig. 3A). The average strength of the RAD51D-K113R:XRCC2 interactions 
was 75% or 57% of the wild type RAD51D:XRCC2 interaction (dependent on the orientation of the 
Gal4-fusion), and the average strength of RAD51D-K113A:XRCC2 interactions was very close to wild 
type levels (100% and 90%, depending on the orientation tested; see Fig. 3A).  
 Strikingly, both B-motif mutants displayed greatly reduced interaction with XRCC2 in either fusion 
orientation (Fig. 3A). The average strength of the RAD51D-V203E:XRCC2 interactions was determined 
to be at 1% and 3% of the wild type interaction, and the average strength of the RAD51D-D206A:XRCC2 
interactions was at 3% and 11% of the wild type interaction (depending on the orientation tested). To 
ensure that the RAD51D mutants are produced in amounts adequate to detect positive protein interactions 
in the yeast two-hybrid system, we tested the protein expression levels for Gal4-RAD51D and its mutant 
forms by immunoblotting of total protein extracts (Fig. 3C). As for the wild type, all mutant forms of the 
Gal-RAD51D fusions were produced at high levels in yeast. Although K113R, V203E, and D206A were 
repeatedly expressed at slightly lower levels than the wild type and K113A, the failure of XRCC2 to 
interact with V203E and D206A is not due to the unavailability of these mutant proteins in yeast. For 
example, even though K113R and V203E are expressed at similar levels, they differ greatly in their 
ability to interact with XRCC2 (see Fig. 3C). 
 
Inability of RAD51D Walker B mutants to interact with RAD51C in the yeast three-hybrid system 
 
The interaction between human RAD51D and RAD51C, when tested in the yeast two-hybrid system, is 
comparatively weak, making it difficult to quantitatively assess protein-protein interactions that 
potentially are reduced even further. However, co-expression of RAD51B, in a non-fused form, has been 
shown previously to greatly enhance the strength of the RAD51D:RAD51C interaction in a yeast three-
hybrid system (40). Furthermore, in vivo a stable RAD51D-RAD51C heterodimer has not been 
discovered, whereas RAD51D and RAD51C were shown to be part of the heterotetramer that also 
contains RAD51B and XRCC2 (20-22,24). For these reasons, we used the yeast three-hybrid system to 
assess the ability of either wild type or mutant RAD51D to interact with RAD51C when RAD51B is co-
expressed. We found that the average strength of interactions between Walker A K113R and RAD51C 
was reduced to 60% of the wild type level, and the average strength of interactions between Walker A 
K113A and RAD51C was at 67% of the wild type interaction (Fig. 3B). Notably, the interactions between 
9RAD51D Walker B mutants and RAD51C were virtually eliminated, not differing from the negative 
control (Fig. 3B). 
No co-immunoprecipitation of RAD51D Walker B mutants with hamster Xrcc2 
 
To investigate in vivo complex formation between wild type or mutant human RAD51D and hamster 
Xrcc2, we performed reciprocal co-immunoprecipitation in extracts from rad51d clones that stably 
express the ectopic proteins at similar levels. We found that hamster Xrcc2 is present specifically in anti-
RAD51D immunoprecipitated complexes from clone WT2 (which overexpresses wild type RAD51D) 
and not immunoprecipitated using IgG control antibody (Fig. 4A). In addition, CHO cells appear to 
express two isoforms of Xrcc2 (as indicated by the double arrows in Fig. 4A-C) that both bind to 
RAD51D. The faster migrating isoform displays the same mobility as recombinant human XRCC2 (Fig. 
4C), while the second isoform appears to be larger and migrates with a shift that corresponds to a 2-3 kD 
difference in molecular weight. It is likely, but not clear yet, that this larger form of hamster Xrcc2 may 
be a modified version of the protein. We also have observed both isoforms of Xrcc2 in V79 hamster cells 
but not in mouse mammary epithelial cells (data not shown). Importantly, Xrcc2 was present in anti-
RAD51D immunoprecipitated complexes from rad51d cells overexpressing A-motif mutants (K113R and 
K113A), but absent in anti-RAD51D immunoprecipitated complexes from B-motif mutants (D206A and 
V203E; Fig. 4B). Although reproducibly at lower levels compared to the wild type expressing line (WT2; 
here: GKT), Xrcc2 was always present in anti-RAD51D immunoprecipitated complexes from clones 
GAT4 and GRT6, which overexpress Walker A K113A and K113R mutant protein, respectively. Anti-
RAD51D immunoprecipitated complexes from parental AA8 and rad51d cells contained neither 
RAD51D nor Xrcc2, demonstrating the inability of the anti-RAD51D antibody to recognize the hamster 
Rad51D protein in AA8 cells and the absence of human RAD51D in rad51d cells. 
 In reciprocal experiments we analyzed anti-Xrcc2 immunoprecipitated complexes from all cell lines 
for the presence of RAD51D (Fig. 4C). We found that the amounts of endogenous Xrcc2 directly 
precipitated by anti-XRCC2 antibody varied greatly among all cell lines tested (even though their 
expression levels for ectopic RAD51D were comparable; see Fig. 1). Only small amounts of Xrcc2 were 
precipitated from extracts of rad51d cells and rad51d cells expressing Walker B-motif mutants D206A or 
V203E (Fig. 4C). Significantly larger amounts of Xrcc2 were precipitated from cells overexpressing wild 
type RAD51D, K113R or K113A, and from AA8 cells. (Note: For AA8 cells only 1/16 of the amount of 
the precipitated complex was loaded onto the gel, relative to all other cell lines). We reproducibly 
detected wild type RAD51D (here: GKT), K113R, and K113A in anti-Xrcc2 immunoprecipitated 
complexes (Fig. 4C, lower panel). Not surprisingly, only small amounts of Walker B mutant proteins 
were present in anti-Xrcc2 complexes from rad51d cells overexpressing either V203E or D206A (Fig. 
4C). In sum, these results show that ectopically expressed wild type RAD51D, or RAD51D with 
mutations in the Walker A motif, formed a stable complex with hamster Xrcc2. Conversely, motif-B 
mutants, although expressed at similar levels, had reduced levels of hamster Xrcc2, probably due to the 
inability to stabilize this protein as a RAD51D-Xrcc2 heterodimer (Fig. 5C; see Discussion).  
 
Greatly impaired interaction of XRCC2-K54A and RAD51D in the yeast two-hybrid system 
 
As we observed little decrease in interaction between RAD51D A-motif mutants and Xrcc2/XRCC2 both 
in vivo and in the yeast two-hybrid system, we hypothesized that XRCC2’s Walker A motif participates in 
nucleotide-binding within the XRCC2-RAD51D heterodimer. Interestingly, a newly identified Rad51 
paralog in S. pombe, Rlp1, having homology to human XRCC2 shows a conserved Walker A motif but no 
clearly defined Walker B motif (46). Therefore, we made the conservative K54R and non-conservative 
K54A substitutions in the Walker A motif of XRCC2, using previously described yeast two-hybrid 
plasmids (40), and assayed their interaction with wild type RAD51D, RAD51D-K113R or RAD51D-
K113A qualitatively and in both orientations by X-Gal filter assay (Fig. 5A and 5B, respectively). 
10
XRCC2-K54A was greatly impaired in binding to wild type RAD51D and mutant RAD51D (Fig. 5A and 
5B, respectively; light blue and white colonies). However, XRCC2-K54R was able to interact with wild 
type RAD51D and both motif-A mutants of RAD51D (Fig. 5A and 5B, respectively). In addition, we 
introduced L148S or D149A amino acid substitutions within the Walker B motif of XRCC2 and assessed 
whether these XRCC2 mutants could interact with wild type RAD51D in the yeast two-hybrid system. 
Both XRCC2-L148S and XRCC2-D149A were impaired in binding to wild type RAD51D, although B-
motif mutants of XRCC2 appeared to be less detrimental to the XRCC2:RAD51D interaction than B-
motif mutants of RAD51D (Fig. 5C; see Discussion).  
 
DISCUSSION 
 
To our knowledge we have described the first human ATPase with disparate requirements for two 
highly conserved Walker A/B motifs, both of which are generally crucial components of the nucleotide-
binding site. Because of the complete loss of RAD51D function caused by amino acid substitution within 
its conserved B motif, the contrasting finding, of normal biological function for GKT substitutions within 
the A motif, was quite unexpected. Moreover, a recent study of mouse Rad51D using rad51d mouse cells, 
in which only A-motif mutants were examined, reached the opposite conclusion, “that conservation of 
Walker Motif A is required for a physiological role of RAD51D” (39). Relative to the wild type control, 
these authors reported ~90% decrease in cell survival after exposure to MMC for K113R and K113A 
mutants in bulk transfected cell populations. However, these investigators did not perform standard MMC 
dose-response measurements to calculate the dose-reduction factor of cell sensitivity associated with the 
mouse Rad51D mutant forms. Since we also observed a slightly increased sensitivity to MMC (calculated 
by dose-reduction factor) under some conditions for both acute and chronic exposures (Fig. 2B and Fig. 
2C), the only discrepancy between our survival data and theirs is the extent of reduced complementation 
by the A-motif mutants.  
 In addition, Gruver et al. reported moderately impaired interactions of mouse Rad51D A-motif 
mutants with Xrcc2, but strongly impaired interactions with Rad51C in the yeast two-hybrid system. 
Although we also found greatly impaired interactions between the human RAD51D Walker A mutants 
and RAD51C in yeast two-hybrid experiments when monitored qualitatively (data not shown), in the 
yeast three-hybrid system we found that these interactions were only moderately affected when tested in 
the presence of RAD51B. As discussed in the Results above, we believe that the yeast three-hybrid 
system more closely reflects the in vivo interaction context.  
Similar to our finding of gross defects associated with the B-motif D206A mutant of RAD51D, 
human XRCC3 substitution at the corresponding aspartate (D213N) dramatically reduced MMC 
resistance when expressed in hamster xrcc3 irs1SF cells (37). As suggested by others (31,37), substitution 
of this highly conserved aspartate likely disrupts ATP binding and/or hydrolysis activity. Nonetheless, 
XRCC3 does behave differently from RAD51D in that both Walker motifs are critical for XRCC3’s 
function (35,37).  
 We presented evidence that alterations in the Walker B motif of RAD51D (V203E or D206A 
substitutions) greatly impair RAD51D-XRCC2 complex formation. Co-immunoprecipitation clearly 
shows that, in the presence of these non-complementing RAD51D mutant proteins, there is much less 
hamster Xrcc2 protein than under conditions where complementing RAD51D (i.e. wild type or motif-A 
mutants) is available. It is important to note from these experiments that the rad51d knockout cell line 
itself (i.e. untransfected) also expresses greatly reduced levels of endogenous Xrcc2 protein when 
compared to its AA8 parent line, which expresses wild type hamster Rad51D (Fig. 4C). Our findings are 
consistent with several studies showing the stabilization of RAD51 paralogs by each other in vivo 
(7,22,47,48), but our data additionally demonstrate that the ability to interact directly is required for this 
stabilization. In addition, neither Walker B-motif mutant is able to interact with the RAD51B:RAD51C 
heterodimer in the yeast three-hybrid system.  
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 The loss of RAD51D-XRCC2 and RAD51D-RAD51C interactions by disruption of nucleotide 
binding (V203E or D206A substitutions) raises the question of which biochemical defect (nucleotide 
binding or protein-protein interaction) is responsible for the cellular phenotype of high sensitivity to 
MMC. Our preferred view is that the role of the ATPase activity that is blocked by the V203E and D206A 
substitutions is to mediate a conformational change that promotes tight binding of RAD51D with XRCC2 
and/or RAD51C. In this model ATPase site integrity and protein interaction are inseparable.  
 Reiterative changes in protein conformation are important for the assembly of multi-subunit protein 
complexes that function in DNA repair (for review see (49)). Rad51 family members induce these 
conformational changes, necessary to fulfill protein function, by binding and hydrolysis of ATP (for 
review see (30)). X-ray crystal structures (50-54) and electron microscopy reconstructions (53-55) of 
several Rad51 homologs have provided evidence that ATP-binding occurs at the subunit interface by 
contacting several highly conserved residues on neighboring subunits. We surmise that human RAD51D, 
through its Walker B motif, may rely on the A motif of another RAD51 paralog to form an active 
ATPase.  
 Overall, our results suggest that RAD51D must form a complex with XRCC2 and/or RAD51C to 
maintain cellular resistance to MMC. We showed that both interactions require a normal RAD51D 
Walker B motif, but not an intact A motif. We speculate that the binding of ATP to RAD51D occurs 
through its Walker B box as part of a bipartite nucleotide-binding site interacting with XRCC2 and/or 
RAD51C, as illustrated in Fig. 6. In Fig. 6A, the B motif of RAD51D interacts with the A motif of 
XRCC2. We showed that mutations in either of these motifs block the interaction; disruption of the 
XRCC2 A motif via K54A substitution (but not K54R substitution) greatly diminishes its binding to 
RAD51D in the yeast two-hybrid system (Fig. 5A and 5B). One published observation is inconsistent 
with the idea that the RAD51D-XRCC2 interaction is important for efficient DNA repair. In that study, 
the XRCC2 A-motif K45A mutant showed only modest decrements in MMC resistance in irs1 V79 cells 
transfected with mutant proteins (36) (although Western blotting of these transfectants was not used to 
standardize the expressed XRCC2 protein levels). Moreover, in our yeast two-hybrid studies amino acid 
substitutions within the Walker B motif of XRCC2, though clearly affecting the XRCC2:RAD51D 
interaction, appear to be less deleterious to XRCC2:RAD51D complex formation in comparison with the 
RAD51D B-motif mutants (Fig. 5C). Fig. 6B depicts an ATPase site composed of the B motif of 
RAD51D and the A motif of RAD51C. Similar to our results for the B motif of RAD51D, mutations in 
the A motif of RAD51C also cause 80-100% loss of DNA repair efficiency (34). Although RAD51D-
RAD51C interactions were not examined in that study, we found a severe RAD51D:RAD51C interaction 
defect in the yeast three-hybrid system for the RAD51D B-motif mutants (Fig. 3). 
 In conclusion, we provide evidence that the Walker B motif of human RAD51D is critically 
important for complex formation with other RAD51 paralogs and for cellular resistance to ICLs. Since 
both Walker B-motif substitutions (V203E and D206A) yielded a similar phenotype, we propose that 
these substitutions not only abrogate ATP hydrolysis, but also simultaneously prevent one or more critical 
interaction(s) and conformational changes underlying RAD51D’s participation in complexes, whose 
integrity is necessary for recombinational repair.  
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FIGURE LEGENDS 
 
Figure 1. Representative Western blots showing the expression levels for wild type human RAD51D and 
its mutant forms in clonal isolates of stably transfected hamster rad51d cells. (A) rad51d clones 
expressing wild type human RAD51D, Upper panel: anti-RAD51D antibody; lower panel: anti-QM 
antibody (loading control). Extracts from untransfected rad51d cells is in left lanes of panels A-D. (B)
rad51d clones expressing RAD51D-K113R (GRT1-GRT6) or RAD51D-K113A (GAT5 and GAT6); 
loaded for comparison; lower panel as in A. (C) rad51d clones expressing RAD51D-K113A (GAT2-
GAT5) or wild type RAD51D (WT2; loaded for comparison purposes); lower panel as in A. (D) rad51d 
clones expressing RAD51D-D206A or RAD51D-V203E. Extract of clone WT2 (expressing wild type 
RAD51D) monitored for comparison purposes; lower panel as in A. The asterisk indicates that V203E 
runs with slightly slower mobility. “WB” indicates antibody used in Western blot analysis. (E) Domain 
structure of the RAD51D protein illustrating the amino acid substitutions introduced into the RAD51D 
cDNA. A: Walker A motif; B: Walker B motif. Highly conserved residues are underlined in the wild type 
sequence. Amino acid substitutions introduced are bold italics. Numbers indicate residue location within 
the primary sequence of RAD51D.  
 
Figure 2. Cell survival determined by colony formation assay after acute or chronic exposure to MMC. 
(A) Parental lines and high-expressing transfectants carrying Walker A-motif mutations were exposed to 
MMC for 60 min. AA8, solid squares; 51D1Lox (Rad51d+), open squares; 51D1 (rad51d) expressing 
wild type human RAD51D (WT2), half-filled squares; 51D1 expressing Walker A-motif mutant, clone 
GAT4, solid diamonds; 51D1 expressing Walker A-motif mutant, clone GRT6, solid circles. (B) Parental, 
mutant (clone: 51D1), and low-expressing transfectants carrying Walker A-motif mutations were exposed 
to MMC for 60 min. Mutant 51D1 (rad51d), open diamonds; 51D1 expressing Walker A-motif mutant, 
clone GAT2, solid diamonds; 51D1 expressing Walker A-motif mutant, clone GRT2, solid triangle; 51D1 
expressing Walker A-motif mutant, clone GRT3, solid circle; for AA8, 51D1Lox, and 51D1 expressing 
wild type RAD51D (here clone WT1) symbols same as in panel A. Horizontal line indicates D37 survival. 
(C) Survival of colony-forming ability in response to continuous MMC exposure of rad51d cells and 
transfectants expressing either wild type RAD51D (WT; open squares), K113R (open triangles), K113A 
(open circles), V203E (open diamonds), D206A (closed triangles). AA8 cells (closed circles) and rad51d 
cells transfected with the empty vector (pcDNA3.1/hygro; black cross) are shown for comparison. Error 
bars that are visible are ± 1 standard deviation from 3 independent experiments. 
 
Figure 3. Yeast two- and three-hybrid analyses of the interactions of wild type or mutant RAD51D with 
XRCC2 or the RAD51C:RAD51B heterodimer, respectively. (A) Quantitative assessment of the 
RAD51D:XRCC2 interaction: -galactosidase units determined photospectrometrically by using o-
nitrophenyl--galactopyranoside as a substrate (one unit corresponds to OD420nm/min/mg protein). (B)
Quantitative assessment of the RAD51D:RAD51B:RAD51C interaction: -galactosidase units 
determined as in A. Results in A and B are from three to five different colonies for every interaction, each 
assayed in triplicate. Error bars represent ± 1 standard error of the mean; error bars that are not visible are 
too small to display. DBD = DNA binding domain of Gal4; AD = transactivating domain of Gal4; NF = 
non-fused protein (here: RAD51B). (C) Western blot to monitor the expression of Gal4-RAD51D wild 
type and mutant forms in yeast Y190U-ura- transformants. Three colonies for each transformation were 
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tested, and a representative blot is shown. Upper panel, anti-RAD51D antibody; lower panel, anti-actin 
antibody loading control. 
 
Figure 4. RAD51D wild type and motif-A mutants allow complex formation with hamster Xrcc2 in vivo.
(A) Crude extract from clone WT2 (overexpressing wild type human Rad51D) immunoprecipitated with a 
polyclonal antibody against RAD51D. Precipitated RAD51D (upper panel) and co-precipitated Xrcc2 
(lower panel) were detected by Western blot analysis on the same membrane. A mock immunoprecipitate 
by incubation of WT2 extracts with IgG control antibody is shown in the far left lane. For comparison 
purposes, whole cell extract from clone WT2 is shown in the far right lane. Note: Xrcc2 is present in two 
isoforms in CHO cells (strain AA8 and derivatives; see also panel C). “HC” indicates cross-reacting 
heavy chain signal. “IP” indicates antibody used for immunoprecipitation. “WB” indicates antibody used 
in Western blot. (B) Presence of Xrcc2 in anti-RAD51D immunoprecipitated complexes from clones 
WT2 (GKT), GRT6 (K113R), and GAT4 (K113A). Xrcc2 is not present in anti-RAD51D complexes 
from parental AA8 (lane 2) or rad51d cells (neither cell line expresses human RAD51D that is 
precipitated here). For comparison, crude extracts from human cells (HeLa; far left lane), WT2 cells 
(GKT; second lane from the right), and AA8 cells (far right lane) are shown. Upper and lower panels: 
Western blot probed with Rad51D and XRCC2 antibodies, respectively. (C) Endogenous hamster Xrcc2 
is expressed at higher levels in cell lines expressing complementing RAD51D (GKT, K113R, K113A) 
that is able to interact with Xrcc2. Upper panel: Western blot probed with anti-XRCC2 antibody shows 
two Xrcc2 isoforms in Xrcc2 immunoprecipitated complexes from rad51d, K113R, K113A, D206A, 
V203E, and GKT cell lines. Precipitated Xrcc2 from AA8 cells is shown for comparison (far left lane; 
note that only 1/16 of the precipitated complex relative to all other cell lines was loaded in order to avoid 
a very strong signal for Xrcc2). Two different concentrations of recombinant human XRCC2/(His)6-
RAD51D complex isolated from insect cells (second and third lanes from the left) and crude extract from 
clone WT2 (GKT; far right lane) are included. Lower panel: same blot probed with RAD51D antibody to 
detect human RAD51D that co-immunoprecipitated with hamster Xrcc2. Note: recombinant human His6-
tagged RAD51D migrated more slowly than human RAD51D.  
Figure 5. Yeast two-hybrid analysis of the interactions between Walker A/B mutants of XRCC2 and 
RAD51D. (A) Greatly impaired XRCC2-K54A interaction with wild type RAD51D. Qualitative 
assessment: expression of -galactosidase by X-gal filter assay; blue patches indicate the expression of 
interacting proteins; one representative colony is shown. (B) Pair wise analyses of the interaction between 
Walker A mutants from both XRCC2 and RAD51D. Qualitative assessment: as in A. (C) Comparative 
analysis of the interaction between either XRCC2-L148S or XRCC2-D149A and RAD51D or between 
XRCC2 and RAD51D-D206A. Results are from three different colonies for every interaction, each 
assayed in triplicate. Error bars represent ± 1 standard error of the mean. DBD = DNA binding domain of 
Gal4; AD = transactivating domain of Gal4.  
 
Figure 6. Possible configurations of RAD51D interactions involving bipartite Walker A and B nucleotide 
binding motifs. (A) The RAD51D-XRCC2 heterodimer requires both the B motif of RAD51D and the A 
motif of XRCC2. (B) The RAD51D-RAD51C heterodimer requires the B motif of RAD51D; a 
requirement for the A motif of RAD51C is predicted but not yet been tested. Neither heterodimer requires 
the A motif of RAD51D. The possible role of the B motif of RAD51C has not been tested.  
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